SGLT2i DM CKD

active
URL
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678
Version
20231006
PublisherOptum StewardDate2023-10-06T01:03:19-04:00Purpose

(Clinical Focus: Medications containing SLGT2 inhibitors that have evidence for benefit in CKD per the ADA Standards of Care in Diabetes 2023),(Data Element Scope: DRUG_CLASS_MEMBERS: PHARMACOLOGIC:),(Inclusion Criteria: RxCUIs for medications containing one of the following: * Canagliflozin * Dapagliflozin * Empagliflozin),(Exclusion Criteria: None)

Expansion
<<>>>
CodeDisplaySystem
1992831http://www.nlm.nih.gov/research/umls/rxnorm
1602118http://www.nlm.nih.gov/research/umls/rxnorm
1862686http://www.nlm.nih.gov/research/umls/rxnorm
1545663http://www.nlm.nih.gov/research/umls/rxnorm
1665369http://www.nlm.nih.gov/research/umls/rxnorm
1373464http://www.nlm.nih.gov/research/umls/rxnorm
1593072http://www.nlm.nih.gov/research/umls/rxnorm
1810996http://www.nlm.nih.gov/research/umls/rxnorm
2359356http://www.nlm.nih.gov/research/umls/rxnorm
1545149http://www.nlm.nih.gov/research/umls/rxnorm
1602109http://www.nlm.nih.gov/research/umls/rxnorm
2359278http://www.nlm.nih.gov/research/umls/rxnorm
1488569http://www.nlm.nih.gov/research/umls/rxnorm
1664318http://www.nlm.nih.gov/research/umls/rxnorm
1545156http://www.nlm.nih.gov/research/umls/rxnorm
1593833http://www.nlm.nih.gov/research/umls/rxnorm
1373467http://www.nlm.nih.gov/research/umls/rxnorm
1811010http://www.nlm.nih.gov/research/umls/rxnorm
1545664http://www.nlm.nih.gov/research/umls/rxnorm
1664323http://www.nlm.nih.gov/research/umls/rxnorm